United States
Print page content Print
Increase text size Decrease text size
Text Size

TELAZOL® CIII

(tiletamine and zolazepam for injection)

Rapid-Acting Anesthetic Combination for Use in Dogs and Cats

Telazol

INDICATIONS:

Dogs:

  • For induction of general anesthesia followed by maintenance with an inhalant anesthetic
  • For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.*

Cats:

  • For restraint or for anesthesia combined with muscle relaxation.

To learn more about Telazol IV Induction claim, click here.

For Frequently Asked Questions, click here.

Collapse All
    • Rapid-acting anesthetic combination of tiletamine and zolazepam

    • Versatile:
      - Administer IV for rapid induction
      - Administer IM for restraint and analgesia
    • Supplied as a sterile powder for reconstitution

    • Low dose volume for IV or IM administration

    • Extended Shelf-life: Can be used for 7 days when stored at room temperature or 56 days when refrigerated.

  • DOSING:

    Induction of General Anesthesia 
    Dogs: 1-2 mg/lb (2.2-4.4 mg/kg), intravenously

    Diagnostic purposes:
    Dogs:  3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) intramuscularly
    Cats: 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) intramuscularly

    Minor procedures:
    Dogs: 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) intramuscularly
    Cats: 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) intramuscularly


     


IMPORTANT SAFETY INFORMATION:

Do not use TELAZOL in dogs and cats with pancreatic disease or severe cardiac or pulmonary dysfunction. Do not use for Caesarean section. Safe use in pregnant dogs or cats has not been established. Use in cats with renal dysfunction is not recommended; pre-existing renal disease may prolong duration of anesthesia. When used for induction of anesthesia, patients should be continuously monitored. Do not use phenothiazine derivative drugs concomitantly with TELAZOL when given at the IM dosages, as the combination produces respiratory and myocardial depression, hypotension, and hypothermia. Pulmonary edema has been reported in cats. Respiratory depression may occur following administration of high doses of TELAZOL. Post-induction apnea may occur when Telazol is administered IV as an induction agent. Common adverse events included hypotension, hypothermia, elevated body temperature and decreased SPO2; frequency varied based on the type of premedication used. See full Prescribing Information.

PAS-00056